Cullinan Therapeutics (CGEM) Cash from Financing Activities (2020 - 2026)

Cullinan Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $380000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $380000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 99.45% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 99.59% from the prior year.
• Cash from Financing Activities declined to $380000.0 in Q1 2026 per CGEM's latest filing, from $715000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $262.2 million in Q2 2024 and bottomed at -$32.9 million in Q4 2022.
• The 5-year median for Cash from Financing Activities is $1.3 million (2024), against an average of $18.8 million.
• Across the five-year window, Cash from Financing Activities tumbled 1318.06% in 2022 and jumped 1817.64% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$32.9 million in 2022, then jumped by 100.75% to $248000.0 in 2023, then surged by 537.9% to $1.6 million in 2024, then plunged by 54.8% to $715000.0 in 2025, then plunged by 46.85% to $380000.0 in 2026.
• Per Business Quant, the three latest CGEM Cash from Financing Activities figures stand at $380000.0 (Q1 2026), $715000.0 (Q4 2025), and $373000.0 (Q2 2025).